ArticleApoptosis : an international journal on programmed cell death2026
Succinate drives breast cancer bone metastasis by activating the HIF1α/YTHDF1/YAP signaling axis to upregulate chemokine CXCL5 and disrupt the bone microenvironment.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aimed to clarify how the metabolite succinate contributes to breast cancer (BC) bone metastasis by upregulating the chemokine CXCL5, mediated through the HIF1α/YTHDF1/YAP signaling pathway, ultimately altering the bone microenvironment. A murine bone metastasis model was established using 4T1 BC cells. Tumor progression and osteolysis were monitored via in vivo imaging (IVIS) and micro-computed tomography (micro-CT). Integrated metabolomics and RNA-seq analyses identified key alterations. The proposed signaling axis was validated using Western blot, RT-qPCR, Chromatin Immunoprecipitation (ChIP-qPCR), m6A RNA immunoprecipitation (MeRIP-qPCR), and luciferase reporter assays. Macrophage polarization was analyzed by flow cytometry. Functional impacts on bone cells were assessed using osteoblast mineralization and osteoclast tartrate-resistant acid phosphatase (TRAP) staining assays. Metabolomic profiling revealed significant succinate enrichment. Succinate activated HIF1α via its receptor SUCNR1. HIF1α transcriptionally upregulated YTHDF1, which subsequently stabilized YAP mRNA via an m6A-dependent mechanism. YAP directly bound to the CXCL5 promoter, enhancing its expression. In vitro, succinate-induced CXCL5 promoted tumor-associated macrophage (TAM) polarization, inhibited osteoblast function, and activated osteoclasts. In vivo, succinate-treated mice exhibited enhanced bone metastasis, severe osteolysis, elevated serum CTX-I, and reduced OCN levels. Succinate drives BC bone metastasis by activating the HIF1α/YTHDF1/YAP/CXCL5 axis, which reprograms the bone microenvironment. This study reveals a novel metabolic-inflammatory-bone niche interplay, identifying CXCL5 as a potential therapeutic target.
Indexed as
Identifiers
42228026What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.